Back to search

Article

A patient-derived xenograft model of <i>FUS::TFCP2</i> intraosseous rhabdomyosarcoma reveals chemoresistance and differential sensitivity to ALK inhibitors

2026-08-06

Abstract excerpt

TFCP2 -rearranged rhabdomyosarcoma is an exceptionally rare and highly aggressive malignancy driven by TFCP2 gene fusions and associated with a dismal clinical prognosis. Because standardized treatment regimens are lacking, developing representative preclinical models is critical for identifying effective therapies. Here, we present a case of a 29-year-old male with rapidly progressive, metastatic pelvic intraosse...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8ff3d8c1-7ab3-5faf-8b0c-f9bf0f27c07c
DOI
10.64898/2026.08.05.743043
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A patient-derived xenograft model of <i>FUS::TFCP2</i> intraosseous rhabdomyosarcoma reveals chemoresistance and differential sensitivity to ALK inhibitorsDOI 10.64898/2026.08.05.743043
Diagnostic and Therapeutic Implications of a FUS :: TFCP2 Fusion and ALK Activation in a Metastatic RhabdomyosarcomaSemantic proximity
Multidimensional Characterization of Soft-Tissue Sarcomas with FUS-TFCP2 or EWSR1-TFCP2 FusionsSemantic proximity
Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusionsSemantic proximity
Larotrectinib for the treatment of TRK fusion solid tumorsSemantic proximity
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primarySemantic proximity
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity
Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomasSemantic proximity
Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agentsSemantic proximity
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.Semantic proximity
Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacitiesSemantic proximity
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic targetSemantic proximity
A call to ARMS: targeting the<i>PAX3-FOXO1</i>gene in alveolar rhabdomyosarcomaSemantic proximity
Select a neighboring publication to make it the new centre.